/PRNewswire/ Jiangsu Recbio Technology Co., Ltd. (Recbio), a China-based company focused on the development of innovative vaccines for major diseases,.
DUBAI: When a handful of pharmaceutical firms began the roll-out of COVID-19 vaccines in early 2021, many thought the worst of the pandemic was over. Indeed, the idea of a tangible weapon against the virus that had killed millions and devastated economies worldwide was temporarily empowering. Within months, a selection of vaccines hit the market, with countries racing to
/PRNewswire/ The Philippines has approved Recombinant Two-Component COVID-19 Vaccine (ReCOV) developed by Jiangsu Recbio Technology Co., Ltd. ("Recbio") for.